The firm is a family office spin-off established in 2023 with offices in New York and Toronto, Canada. The firm invests globally through two complementary arms. The early-stage arm focuses on Pre-Seed and Seed opportunities in North America, typically writing first checks between USD $500k–2.5M into deeptech companies. The later-stage arm is dedicated exclusively to life sciences investments, with flexibility on check sizes and a global focus. While the firm does not typically lead rounds, it participates actively on a case-by-case basis.
The early-stage strategy emphasizes deeptech companies—such as biotech, AI, space-tech, and medtech—while generally avoiding pure life sciences unless there is a strong technology angle, such as medical devices. The later-stage strategy targets Phase I–III ready drug assets. The firm is disease-agnostic, including orphan indications, but prefers companies addressing at least 5% of the population. Across both strategies, the firm favors companies pursuing FDA approval in the U.S.
The firm does not have strict company or management team requirements, but appreciates teams with academic backgrounds or ties to universities.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment